An independent study of 139 NSCLC patients with WHO performance status of 0 or 1 who received gefitinib reported that patients with the EGFR haplotype of −216G/−191C had significantly worse survival with a hazard ratio of 1.85 (95% CI: 1.09 to 3.12) after adjusting for performance status, previous platinum treatment, skin rash, and diarrhea [57]. Here, EGFR is linked to non-small cell lung carcinoma.